Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05554068
Other study ID # 215468
Secondary ID
Status Recruiting
Phase Phase 2
First received
Last updated
Start date March 7, 2023
Est. completion date November 1, 2026

Study information

Verified date March 2023
Source Loyola University
Contact Patrick A Hagen
Phone 708-327-3810
Email patrick.hagen@lumc.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a phase II study that will examine the immunogenicity of the Shingrix vaccine in patients following an allogeneic stem cell transplant.


Description:

Cell mediated immunity is severely compromised after an allogeneic stem cell transplantation. This results in an increased risk of zoster with its associated morbidity and mortality. Patients typically receive prophylactic antivirals for 1 year after AlloSCT which reduces the incidence of zoster during this period. Unfortunately, after completing prophylaxis, patients continue to be at a significantly increased risk of zoster with an incidence rate of up to 29% at 3-years post transplant. The recombinant zoster vaccine provides immunogenicity and has shown clinical efficacy in preventing zoster in patients who have received an autologous transplant. Furthermore, it has been shown to be safe in patients who had received an allogeneic transplant in a retrospective study although immunogenicity seemed to be decreased in this cohort. Due to the paucity of data in allogeneic recipients, we propose a prospective, non-randomized study to evaluate the immunogenicity and clinical efficacy of the recombinant zoster vaccine in recipients of allogeneic stem cell transplantation. As a secondary endpoint, we will compare our results to historical data of immunogenicity and clinical effectiveness of the vaccine in autologous transplant recipients.


Recruitment information / eligibility

Status Recruiting
Enrollment 100
Est. completion date November 1, 2026
Est. primary completion date March 7, 2025
Accepts healthy volunteers No
Gender All
Age group N/A and older
Eligibility Inclusion Criteria: - Age =18 years - = 12 months and = 36 months post-AlloSCT - Donor sources: matched related, matched unrelated, cord blood - Any malignant hematological disease including acute leukemia, myelodysplastic syndrome, non-Hodgkin's lymphoma, Hodgkin's lymphoma, chronic lymphocytic leukemia, chronic myeloid leukemia, multiple myeloma, and myeloproliferative disorders. - Any conditioning regimen - Any planned immunosuppressive prophylactic regimen - Patients with chronic graft-versus-host disease on stable immunosuppression - Ability to understand and the willingness to sign a written informed consent. - Negative pregnancy test in female patients of childbearing potential Exclusion Criteria: - Patients who had zoster after an allogeneic transplant and prior to enrollment - Patients who are currently pregnant - History of allergic reactions attributed to compounds of similar chemical or biologic composition to the recombinant zoster vaccine, Shingrix, or other agents used in study. - Patients who have had a relapse of their primary hematological disease - Previous allogeneic stem cell transplantation - Acute disease at the time of vaccination - Thrombocytopenia that in the judgment of the investigator would make intramuscular injection unsafe.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Shingrix
Shingrix vaccine will be given to all eligible patients at one to three year post allogeneic stem cell transplantation.

Locations

Country Name City State
United States Loyola University Medical Center Maywood Illinois

Sponsors (1)

Lead Sponsor Collaborator
Loyola University

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Cell mediated and humoral immune response Measured one month following eh last dose of vaccine received
See also
  Status Clinical Trial Phase
Completed NCT01132729 - Bioequivalency Study of Valacyclovir Hydrochloride 1000 mg Under Fasting Conditions N/A
Completed NCT01132716 - Bioequivalency Study of Valacyclovir Hydrochloride 1000 mg Under Fed Conditions N/A
Completed NCT04099706 - Treatment of Chronic Postherpetic Pain With Autologous Fat Grafting - A RCT N/A
Completed NCT04540081 - Enhancing Electronic Health Systems to Decrease the Burden of Colon Cancer, Lung Cancer, Obesity, Vaccine-Preventable Illness, and LivER Cancer N/A
Completed NCT01527370 - Safety, Tolerability, and Immunogenicity of Zoster Vaccine Live (ZOSTAVAX™) in Healthy Adults in India (V211-025) Phase 3
Completed NCT00534248 - Study to Evaluate the Safety and Effectiveness of Zostavax™ in Subjects 50 - 59 Years of Age (V211-022) Phase 3
Completed NCT01262300 - Vitamin D Supplementation And Varicella Zoster Virus Vaccine Responsiveness In Older Long-Term Care Residents Phase 1
Completed NCT00576108 - A 2 Week Study of Topical KD7040 in the Treatment of Postherpetic Neuralgia (PHN) Phase 2
Completed NCT00109122 - Safety, Tolerability, and the Body's Ability to Develop Resistance to an Investigational Vaccine for Shingles (V211-007) Phase 2
Completed NCT04047979 - Systems Biology of Zoster Vaccine Phase 2
Active, not recruiting NCT05871541 - A First-in-Human Study to Evaluate JCXH-105, an srRNA-based Herpes Zoster Vaccine Phase 1
Completed NCT02114333 - Comparison of a Live Herpes Zoster Vaccine and a Recombinant Vaccine in 50-59 and 70-85 Year Olds Phase 1
Completed NCT00900783 - A Study of FV-100 Versus Valacyclovir in Patients With Herpes Zoster Phase 2
Completed NCT01600079 - ZOSTAVAX™ (Zoster Vaccine Live) Long-term Effectiveness Study (V211-024)
Active, not recruiting NCT02444936 - ZOSTAVAX in Persons Imminently Receiving Chemotherapy for Solid Organ Tumors Phase 4
Recruiting NCT06238726 - Nudging Patients to Increase Shingles Vaccination N/A
Completed NCT02704572 - Optimal Timing of Zoster Vaccine After Zoster Illness N/A
Completed NCT00300222 - Study of NGX-4010 for the Treatment of Postherpetic Neuralgia Phase 3
Terminated NCT02412917 - A Comparative Study of FV-100 vs. Valacyclovir for the Prevention of Post-Herpetic Neuralgia Phase 3
Completed NCT00115310 - Study of NGX-4010 for the Treatment of Postherpetic Neuralgia Phase 3